Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inti Zlobec

Showing results (111-120 of 260) with videos related to

Pageof 26
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 23, 2020
Are tumour grade and tumour budding equivalent in colorectal cancer? A retrospective analysis of 771 patientsInti Zlobec, Heather E Dawson, Annika Blank, et al.
Human Pathology|June 14, 2011
Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patientsAlessandro Lugli, Tatjana Vlajnic, Olivier Giger, et al.
Histopathology|October 1, 2020
Taking tumour budding to the next frontier - a post International Tumour Budding Consensus Conference (ITBCC) 2016 reviewLinda Studer, Annika Blank, John-Melle Bokhorst, et al.
Human Pathology|July 16, 2008
Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomasClaude Fischer, Inti Zlobec, Edith Stöckli, et al.
Frontiers in Medicine|July 19, 2019
Cell Line Derived Xenograft Mouse Models Are a Suitable <i>in vivo</i> Model for Studying Tumor Budding in Colorectal CancerLaurent M C Georges, Olivier De Wever, José A Galván, et al.
The Prostate|September 25, 2014
Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancersAchim Fleischmann, Outi R Saramäki, Inti Zlobec, et al.
Pathology, Research and Practice|May 29, 2021
RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1Sandra Burren, Katharina Reche, Annika Blank, et al.
Histopathology|August 19, 2010
Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancerEva Karamitopoulou, Alessandro Lugli, Ioannis Panayiotides, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2007
Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancerInti Zlobec, Parham Minoo, Kristi Baker, et al.
The American Journal of Surgical Pathology|August 21, 2014
Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approachesEva Karamitopoulou, Svenja Thies, Inti Zlobec, et al.
Pageof 26

Showing results (111-120 of 260) with videos related to

Sort By:
Pageof 26
European Journal of Cancer (Oxford, England : 1990)|March 23, 2020
Are tumour grade and tumour budding equivalent in colorectal cancer? A retrospective analysis of 771 patientsInti Zlobec, Heather E Dawson, Annika Blank, et al.
Human Pathology|June 14, 2011
Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patientsAlessandro Lugli, Tatjana Vlajnic, Olivier Giger, et al.
Histopathology|October 1, 2020
Taking tumour budding to the next frontier - a post International Tumour Budding Consensus Conference (ITBCC) 2016 reviewLinda Studer, Annika Blank, John-Melle Bokhorst, et al.
Human Pathology|July 16, 2008
Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomasClaude Fischer, Inti Zlobec, Edith Stöckli, et al.
Frontiers in Medicine|July 19, 2019
Cell Line Derived Xenograft Mouse Models Are a Suitable <i>in vivo</i> Model for Studying Tumor Budding in Colorectal CancerLaurent M C Georges, Olivier De Wever, José A Galván, et al.
The Prostate|September 25, 2014
Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancersAchim Fleischmann, Outi R Saramäki, Inti Zlobec, et al.
Pathology, Research and Practice|May 29, 2021
RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1Sandra Burren, Katharina Reche, Annika Blank, et al.
Histopathology|August 19, 2010
Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancerEva Karamitopoulou, Alessandro Lugli, Ioannis Panayiotides, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2007
Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancerInti Zlobec, Parham Minoo, Kristi Baker, et al.
The American Journal of Surgical Pathology|August 21, 2014
Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approachesEva Karamitopoulou, Svenja Thies, Inti Zlobec, et al.
Pageof 26